YOLFTbeta
Nkarta Inc

Nkarta Inc

NKTX · NASDAQ · Healthcare / Biotechnology

1.19USD-0.07 (-5.93%)

Price History

Full chart

Market Stats

Previous Close1.27
Open1.28
Day Range1.11 – 1.31
52-Week Range1.70 – 3.72
Volume1.39M
Market Cap191.24M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.54
Dividend Yield0.00%
Beta0.97
50-Day Avg2.58
200-Day Avg2.52

About

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Paul J. Hastings
  • Employees106
  • Headquarters1150 Veterans Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.nkartatx.com

Leadership

  • Mr. Paul J. HastingsCEO & Director · b. 1960
  • Dr. Nadir Mahmood Ph.D.President and Principal Accounting & Financial Officer · b. 1980
  • Dr. Shawn Rose M.D., Ph.D.Chief Medical Officer and Head of Research & Development

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.55M115.39K38500000
Growth (%)--98.24%-99.67%-100.00%----
Cost of Revenue4.25M17.22K1.05M2.12M6.57M5.87M9.15M9.19M
Gross Profit2.30M98.17K-1.05M-2.12M-6.57M-5.87M-9.15M-9.19M
Gross Margin35.08%85.08%-272207.79%-----
Operating Expense2.65M22.45M50.46M84.31M112.38M125.78M119.04M112.01M
Operating Income-356.45K-22.35M-51.51M-86.43M-118.95M-131.65M-128.19M-121.21M
Operating Margin-5.44%-19368.66%-13378701.30%-----
EBITDA-91.29K-20.05M-50.72M-84.67M-116.32M-120.48M-99.64M-94.89M
EBITDA Margin-1.39%-17376.38%-13174545.45%-----
Net Income-274.50K-21.08M-91.36M-83.95M-119.42M-117.50M-108.79M-104.08M
Net Income Margin-4.19%-18265.66%-23730129.87%-----
R&D4.25M17.22M36.22M63.41M90.90M90.90M96.74M90.43M
R&D as % of Total Revenue64.92%14921.31%9407792.21%-----
Interest Expense0473.00K313.00K2.11M5.59M---
Interest Expense % of Total Revenue0.00%409.93%81298.70%-----

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.61M48.41M337.65M273.90M472.94M378.88M501.20M404.21M
Total Liabilities15.00M73.89M16.43M22.94M100.73M105.60M93.23M91.88M
Total Equity-5.40M-25.48M321.22M250.97M372.21M273.29M407.98M312.32M
Cash7.87M20.61M96.69M60.82M37.49M31.04M27.87M39.63M
Total Debt12.71M7.30M8.92M12.46M82.93M88.34M80.27M76.42M
Net Debt4.84M-13.31M-87.77M-48.36M45.44M57.30M52.40M36.79M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.18M-18.37M-43.51M-67.93M-57.00M-86.16M-99.70M-88.70M
Investing Cash Flow-757.88K-18.30M-210.08M32.53M-184.69M79.02M-129.56M100.32M
Financing Cash Flow87.49K49.58M329.82M1.20M219.01M691.00K226.08M141.00K
Capital Expenditure757.88K1.93M7.51M5.03M47.11M28.15M4.41M1.21M
Free Cash Flow-5.94M-20.30M-51.02M-72.95M-104.11M-114.31M-104.11M-89.91M
FCF to OCF114.62%110.50%117.26%107.40%182.65%132.67%104.42%101.36%

Earnings

Report DateApr 20, 2020Aug 20, 2020Nov 12, 2020Mar 25, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 17, 2022May 12, 2022Aug 11, 2022Nov 9, 2022Mar 16, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 9, 2024Aug 13, 2024Nov 7, 2024Mar 19, 2025May 14, 2025Aug 12, 2025Nov 10, 2025Mar 25, 2026May 13, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate0.00-6.71-0.39-0.44-0.52-0.59-0.66-0.90-0.72-0.59-0.62-0.64-0.70-0.68-0.65-0.59-0.56-0.51-0.36-0.40-0.45-0.35-0.30-0.29-0.36-0.39-0.40
EPS Actual-0.69-6.08-0.44-0.55-0.59-0.66-0.68-0.69-0.79-0.61-0.58-0.67-0.63-0.68-0.52-0.57-0.58-0.34-0.39-0.35-0.43-0.31-0.29-0.37-0.37-0.54-
Surprise-9.39%-12.82%-25.00%-13.46%-11.86%-3.03%23.33%-9.72%-3.39%6.45%-4.69%10.00%0.00%20.00%3.39%-3.57%33.33%-8.33%12.50%4.44%11.43%3.33%-27.59%-2.68%-38.46%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap191.24M
Enterprise Value87.74M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1000000.00
Price / Book0.80
EPS-1.54
Book Value3.46
Revenue (TTM)385
Gross Profit (TTM)-36.22M
EBITDA-113.44M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-38.76%
Return on Assets-19.57%
Shares Outstanding71.62M
Shares Float60.52M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 10.83
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
82.80%
Insiders
4.88%
Retail / Other
12.32%

Top Institutional Holders

  • RA Capital Management, LLC
    10.81M15.09%
  • BlackRock Inc
    4.51M6.29%
  • NEA Management Company, LLC
    3.57M4.98%
  • Samsara BioCapital, LLC
    3.51M4.90%
  • SR ONE CAPITAL MANAGEMENT, LP
    3.33M4.65%
  • GSK PLC
    3.15M4.40%
  • Monaco Asset Management
    2.37M3.31%
  • Citadel Advisors Llc
    2.17M3.04%
  • Alyeska Investment Group, L.P.
    2.08M2.91%
  • Vanguard Capital Management, LLC
    2.01M2.81%
  • Two Sigma Investments LLC
    1.87M2.62%
  • Renaissance Technologies Corp
    1.73M2.42%
  • Wasatch Advisors LP
    1.58M2.20%
  • TANG CAPITAL MANAGEMENT LLC
    1.48M2.07%
  • Geode Capital Management, LLC
    1.27M1.77%
  • Acadian Asset Management LLC
    1.26M1.76%
  • State Street Corp
    1.24M1.73%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.57M2.19%
  • Wasatch Ultra Growth
    1.49M2.08%
  • iShares Russell 2000 ETF
    1.13M1.57%